Financial Results QTR 1
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Rekvina Laboratories Limited reported its standalone unaudited results for the quarter ended 30 June 2025. The company had no revenue from operations during the quarter. Total expenses stood at Rs. 3.54 lacs, mainly comprising employee benefits (Rs. 2.70 lacs) and other expenses (Rs. 0.84 lacs). This resulted in a net loss after tax of Rs. 3.54 lacs, slightly narrower than the Rs. 4.28 lacs loss reported in the previous quarter (Q4 FY25) but wider than the Rs. 0.35 lacs loss in the corresponding quarter last year. The full-year FY25 ended with a cumulative loss of Rs. 13.71 lacs. The statutory auditor, Y.M. Shah & Co., issued a clean limited review report with no qualifications.
The company continues to post losses with zero operating revenue, raising questions about the sustainability of its business operations. Shareholders should note the persistent lack of top-line income and the absence of any revenue recovery signals, which may weigh negatively on the stock and investor sentiment.